A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition

Journal of Applied Toxicology

Volumn 32, Issue 12, 2012, Pages 1008-1020

  Hu, Wenyue ^a   Hirakawa, Brad ^a   Jessen, Bart ^a   Lee, Michelle ^a   Aguirre, Shirley ^a  

^a PFIZER INC   (United States)

Author keywords

Cardiotoxicity; PDE inhibition; Tyrosine kinase inhibitor

Indexed keywords

CYCLIC AMP; MILRINONE; PF 04254644; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CARDIOTOXICITY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DISEASE SEVERITY; DOSE RESPONSE; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE DEGENERATION; HEART RATE; IMMUNOFLUORESCENCE; MALE; MICROARRAY ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; TISSUE DEGENERATION;

ANIMALS; CALCIUM; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, REPORTER; MALE; MILRINONE; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84868087111     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2801     Document Type: Article

References (27)

1. Aguirre SA, Heyen JR, Collette W, Bobrowski W, Blasi ER. 2010. Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor. Toxicol. Pathol. 38: 416-428.
2. Bender AT, Beavo JA. 2006. Cyclic nucleotide phosphodiesterases:molecular regulation to clinical use. Pharmacol. Rev, 58: 488-520.
3. Cheng H, Force T. 2010a. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circul. Res. 106: 21-34.
4. Cheng H, Force T. 2010b. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog. Cardiovasc. Dis. 53: 114-120.
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019.
6. Earl CQ, Linden J, Weglicki WB. 1986. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J. Cardio. Pharmacol, 8: 864-872.
7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. 2009. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 15: 2207-2214.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl. J. Med. 356: 125-134.
9. Force T, Kerkela R. 2008. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discov. Today 13: 778-784.
10. Gupta R, Kumar G, Kumar RS. 2005. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity. Meth. Find. Exp. Clin. Pharmacol. 27: 101-118.
11. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12: 908-916.
12. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 353: 172-187.
13. 2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circul. Res. 102: 1091-1100.
14. Liu H, Maurice DH. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125: 1501-1510.
15. Lugnier C. 2006. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109: 366-398.
16. Mellor HR, Bell AR, Valentin JP, Roberts RR. 2011. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120: 14-32.
17. Niles RM. 1998. Control of retinoid nuclear receptor function and expression. Subcell. Biochem. 30: 3-28.
18. Omori, K, Kotera J. 2007. Overview of PDEs and their regulation. Circul. Res. 100: 309-327.
19. Osadchii OE. 2007. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc. Drugs Ther. 21: 171-194.
20. Shen G, Kong AN. 2009. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm. Drug Dispos. 30: 345-355.
21. Stellrecht CM, Gandhi V. 2009. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 280: 1-14.
22. Strevel EL, Ing DJ, Siu LL. 2007. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25: 3362-3371.
23. Toraason M, Breitenstein M. 1988. Prenatal ethylene glycol monomethyl ether (EGME) exposure produces electrocardiographic changes in the rat. Toxicol. Appl. Pharmacol. 95: 321-327.
24. Vandecasteele G, Rochais F, Abi-Gerges A, Fischmeister R. 2006. Functional localization of cAMP signalling in cardiac myocytes. Biochem. Soc. Trans. 34: 484-488.
25. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. 2007. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7: 153.
26. Wang C, Jiang L, Rao J, Liu Y, Yang L, Zhang D. 2010. Evaluation of four genes in rice for their suitability as endogenous reference standards in quantitative PCR. J. Agric. Food Chem. 58: 11543-11547.
27. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. 2008. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106: 153-161.